Design and evaluation of the physical-chemical -material properties parameters: Strategically expanding a prodrug platform for controlled drug delivery

物理化学材料特性参数的设计和评估：战略性扩展用于受控药物输送的前药平台

• 批准号: 556570-2020
• 负责人: Sheardown, Heather
• 金额: $ 12.48万
• 依托单位: McMaster University
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=706483
• 关键词: Design; evaluation; physical; chemical; material

The development of new strategies to improve drug delivery has the potential to significantly improve patient outcomes. Ripple Therapeutics has developed a new approach to developing implants based on a discovery that prodrugs (an inactive version of a drug) can be processed into an implant without the use of a polymer to hold the implant together and control the release rate of the drug. This reduces the amount of drug needed to treat patients by more efficiently controlling how the drug is released from the implant, and prevents exposure of the patient to foreign polymers. In this grant, the discovery that Ripple Therapeutics has made with a class of drugs called corticosteroids will be expanded to other drug classes that would benefit from controlled delivery. An engineering approach will be used to prepare implants made solely of prodrugs using drugs that are standard of care for glaucoma treatment and opioid abuse disorder. The use of prodrugs as a carrier system for controlling the release of other drugs will also be evaluated. The material characteristics of these implants will be assessed. Studies will be performed to determine if these implants can predictably control drug release and prototypes will be prepared and characterized. Safety of the implant materials will also be confirmed. The successful completion of this project will accelerate the development of new treatment options for patients in Canada and internationally, improving quality of life and saving lives.

开发新的策略来改善药物输送有可能显着改善患者的预后。涟漪Therapeutics开发了一种开发植入物的新方法，该方法基于一项发现，即前药（药物的无活性版本）可以加工成植入物，而无需使用聚合物将植入物固定在一起并控制药物的释放速率。这通过更有效地控制药物如何从植入物释放来减少治疗患者所需的药物量，并防止患者暴露于外来聚合物。在这项资助中，涟漪治疗公司用一类称为皮质类固醇的药物所做的发现将扩展到其他药物类别，这些药物将受益于控制输送。工程方法将用于制备仅由前药制成的植入物，所述前药使用作为青光眼治疗和阿片类药物滥用障碍的标准护理的药物。还将评价前药作为控制其他药物释放的载体系统的用途。将评估这些植入物的材料特性。将进行研究以确定这些植入物是否可以可预测地控制药物释放，并将制备和表征原型。还将确认植入材料的安全性。该项目的成功完成将加速为加拿大和国际患者开发新的治疗方案，提高生活质量并挽救生命。